title: Increased circulating Th17 cells after transarterial chemoembolization correlate with improved survival in stage III hepatocellular carcinoma: a prospective study.
abstract: Transarterial chemoembolization (TACE) has therapeutic effects in patients with unresectable hepatocellular carcinoma (HCC), but its impact on the cellular immune response during disease progression is largely unknown. Here we conducted a prospective study to evaluate the effect of TACE on immune status and to identify prognostic immune markers governing treatment success. In this study, 51 stage III HCC patients, 28 stage I HCC patients (TNM classification) and 20 healthy donors were enrolled. Flow cytometry and cytometric bead array were used to evaluate the circulating immune cell subsets, including CD4(+) T cells (Th1, Th17 and Treg cells), CD8(+) T cells, NK cells, and NKT cells, and plasma cytokines before TACE and 30 days after TACE. Interestingly, among those immune parameters, the frequency of circulating Th17 cells was higher in stage III HCC patients than in stage I HCC patients (P = 0.015) and healthy donors (P<0.001). Moreover, an increased frequency of circulating Th17 cells was observed 30 days after TACE (Th17 D30 ) compared with the baseline level (P = 0.036). Kaplan-Meier analysis demonstrated that Th17 D30 was positively associated with overall survival (OS; P = 0.007) and time to progression (TTP; P = 0.009). Multivariate Cox analysis revealed that Th17 D30 was an independent prognostic factor for OS (HR = 0.317, P = 0.032) and TTP (HR = 0.304, P = 0.010). These results provide a potential prognostic marker for stage III HCC patients undergoing TACE and may be useful for identifying patients who can benefit from adjuvant immunotherapies.
authors.affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liao
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Zhi-Liang
authors.initials: ZL
authors.lastname: Huang
authors.forename: Ming
authors.initials: M
authors.lastname: Shi
authors.forename: Xing-Juan
authors.initials: XJ
authors.lastname: Yu
authors.forename: Limin
authors.initials: L
authors.lastname: Zheng
authors.forename: Shengping
authors.initials: S
authors.lastname: Li
authors.forename: Lian
authors.initials: L
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology* / Q000628:therapy*; D008297:Male; D011446:Prospective Studies; D058504:Th17 Cells / Q000276:immunology*; D016896:Treatment Outcome
references.citation: Cell Mol Immunol. 2012 Jan;9(1):1-2
references.pmid: 22157624
references.citation: Oncogene. 2010 Oct 21;29(42):5653-62
references.pmid: 20729908
references.citation: Lancet Infect Dis. 2002 Jan;2(1):43-50
references.pmid: 11892495
references.citation: Immunity. 2011 Dec 23;35(6):972-85
references.pmid: 22177921
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Hepatol. 2011 Apr;54(4):830-4
references.pmid: 21145836
references.citation: Liver Int. 2013 Apr;33(4):595-604
references.pmid: 23402625
references.citation: Blood. 2008 Jul 15;112(2):362-73
references.pmid: 18354038
references.citation: Cancer Cell. 2009 Sep 8;16(3):183-94
references.pmid: 19732719
references.citation: Immunity. 2009 Nov 20;31(5):787-98
references.pmid: 19879162
references.citation: Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):448-58
references.pmid: 20628345
references.citation: Curr Opin Immunol. 2007 Jun;19(3):281-6
references.pmid: 17433650
references.citation: BMC Cancer. 2008 Nov 26;8:349
references.pmid: 19036146
references.citation: J Hepatol. 2001 Sep;35(3):421-30
references.pmid: 11592607
references.citation: Hepatology. 2010 Jan;51(1):154-64
references.pmid: 19902483
references.citation: Oncology. 1997 Jan-Feb;54(1):28-33
references.pmid: 8978589
references.citation: Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1687-93
references.pmid: 21940335
references.citation: Int J Cancer. 2010 May 1;126(9):2164-74
references.pmid: 19739081
references.citation: Chin J Cancer. 2010 Feb;29(2):172-7
references.pmid: 20109346
references.citation: Nat Immunol. 2005 Nov;6(11):1133-41
references.pmid: 16200068
references.citation: J Hepatol. 2009 May;50(5):980-9
references.pmid: 19329213
references.citation: Ann Surg Oncol. 2011 Feb;18(2):413-20
references.pmid: 20839057
references.citation: PLoS One. 2012;7(3):e32493
references.pmid: 22396772
references.citation: Nat Rev Cancer. 2005 Apr;5(4):263-74
references.pmid: 15776005
references.citation: Nat Immunol. 2008 Jun;9(6):650-7
references.pmid: 18454150
references.citation: Sci Transl Med. 2011 Oct 12;3(104):104ra100
references.pmid: 21998407
references.citation: J Vasc Interv Radiol. 2011 May;22(5):702-9
references.pmid: 21514523
references.citation: Cancer Res. 2011 Feb 1;71(3):661-5
references.pmid: 21148486
references.citation: Blood. 2009 Aug 6;114(6):1141-9
references.pmid: 19470694
references.citation: J Exp Med. 2009 Jun 8;206(6):1327-37
references.pmid: 19451266
references.citation: Oncologist. 2010;15 Suppl 4:42-52
references.pmid: 21115580
references.citation: Gastroenterology. 2007 Jun;132(7):2328-39
references.pmid: 17570208
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6770-9
references.pmid: 18980970
references.citation: J Hepatol. 2012 Jun;56(6):1336-42
references.pmid: 22314421
references.citation: Nat Rev Immunol. 2010 Apr;10(4):248-56
references.pmid: 20336152
references.citation: J Hepatol. 2012 Aug;57(2):313-21
references.pmid: 22521360
references.citation: Cancer Cell. 2006 Aug;10(2):99-111
references.pmid: 16904609
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Nature. 2008 Apr 3;452(7187):548-52
references.pmid: 18385728
references.citation: Immunol Rev. 2008 Apr;222:129-44
references.pmid: 18363998
references.citation: Int J Clin Oncol. 2010 Dec;15(6):552-8
references.pmid: 20963618